PolyNovo Limited (PNV.AX)

AUD 2.01

(-5.19%)

Market Cap (In AUD)

1.38 Billion

Revenue (In AUD)

103.19 Million

Net Income (In AUD)

5.26 Million

Avg. Volume

1.57 Million

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.475-2.78
PE
-
EPS
-
Beta Value
1.719
ISIN
AU000000PNV0
CUSIP
Q7704D107
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Mr. Swami Raote BPHARM, M.B.A.
Employee Count
-
Website
https://polynovo.com
Ipo Date
1998-11-30
Details
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.